BioXcel Therapeutics, Inc. Accumulated Amortization, Debt Issuance Costs
BioXcel Therapeutics, Inc. (BTAI) had Accumulated Amortization, Debt Issuance Costs of $321.00 thousand as of 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Notes › Debt Issuance Costs, Net, Alternative
us-gaap:AccumulatedAmortizationDeferredFinanceCosts · last filed 2022-08-11
- 2022-06-30: Accumulated Amortization, Debt Issuance Costs $321.00K.
| Period end | Accumulated Amortization, Debt Issuance Costs |
|---|---|
| 2022-06-30 | $321.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |